Malecare, Author at malecare.org

Survival Advantage of Abiraterone Acetate (Zytiga) in Men with Castrate Resistant Metastatic Advanced Prostate Cancer

We all know that abiraterone acetate (Zytiga) plus prednisone provides a survival advantage for men with castrate resistant advanced prostate cancer (mCRPC) who have had prior treatment with a taxane based chemotherapy. New information has shown that abiraterone acetate offers a somewhat longer overall survival benefit than the data originally presented when the trial halted [...]

By Malecare|2017-10-19T10:50:46-04:00September 19th, 2012|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Combination Therapy, Drugs & Treatments, enzalutamide, Enzalutamide (MDV-3100), MDV3100, Provenge, Uncategorized, Understanding APC|2 Comments

Taxane-Based Chemotherapy Drugs May Be Underestimated, Especially Against Advanced Prostate Cancer

According to researchers at Weill Cornell Medical College in the Sept. 15 issue of the journal Cancer Research, taxne-based chemotherapy drugs are not well understood as they may be more powerful than many have believed. Generally, it is believed that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just stop a cancer cell from dividing -- but [...]

By Malecare|2012-09-18T12:41:03-04:00September 18th, 2012|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, General Information, Research, Uncategorized, Understanding APC|0 Comments

More Information About C11 Choline Scans & Some of the Other Alternative Scans Used to ID Focal Advanced Prostate Cancer Recurrences

Off-line I have received a number of additional questions about the use of imaging with c11 choline (see my post at http://advancedprostatecancer.net/?p=3433). The questions ranged from what is c11 choline to how it compares to some of the other more sensitive PET scans contrasts that are being used to identify specific locations of recurrent advanced [...]

By Malecare|2017-10-19T10:50:56-04:00September 16th, 2012|Advanced Prostate Cancer, Choline C11, General Information, Imaging, Metastases, salvage therapy, Uncategorized, Understanding APC|25 Comments

A Great Stride In PET Imaging, But Not A Panacea – C11 Choline For Diagnosing Recurrent Prostate Cancer

The FDA has approved c11 choline Injection, a Positron Emission Tomography (PET) imaging agent, for use in men to detect prostate cancer recurrences and to locate specific body sites for follow-up tissue sampling, testing and treatment. The indicated use for c11 choline injection is men with elevated prostate specific antigen (PSA) levels after earlier primary [...]

By Malecare|2012-09-14T13:07:20-04:00September 14th, 2012|Advanced Prostate Cancer, Bio Chemical Recurrence, Choline C11, Clinical Trials, Clinical Trials, FDA, salvage therapy, Uncategorized, Understanding APC|2 Comments

So Much Has Happened While I was Away – News About Advanced Prostate Cancer

The summer is coming to a close and I am back, ready to again take on the world. I had the fantastic opportunity of spending almost two weeks in Alaska, a land that is so different from the lower 48. I have to say that I have a new found respect for those individuals who [...]

By Malecare|2012-09-13T12:09:26-04:00September 13th, 2012|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), biomarkers, Bone Metastases, Choline C11, Drugs & Treatments, Early/Expanded Access Programs, enzalutamide, Enzalutamide (MDV-3100), General Information, MDV3100, Provenge, Uncategorized, Understanding APC, Xtandi|0 Comments

IT’S TIME FOR DAD’S WELLNESS

Wellness Wheel When I first got into blogging about six years ago there was this constant urge to, if not overwhelming obsession with, trying to convince the world that good dads existed, especially the so-called good black dad. But in relation to the internet six years ago might as well be sixty. Since then [...]

By Malecare|2022-08-25T16:54:52-04:00September 9th, 2012|Wellness|1 Comment

Getting Early Access Now to Alpharedin (radium-233 chloride) NOW – We Need Your HELP

Our Prostate Cancer community was happy when Bayer and Algeta announced an Early/Expanded Access Program for Alpharedin. However we notice that, as of today, there is only one clinical trial site that is currently open and taking any new patients. However, this site is limited to only 2 men per month and their waiting list [...]

By Malecare|2012-09-05T13:39:20-04:00September 5th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Drugs & Treatments, Early/Expanded Access Programs, Uncategorized, Understanding APC|5 Comments

Breaking News – FDA Approves another New Treatment for Late Stage Advanced Prostate Cancer – Xtandi (MDV3100)

The U.S. Food and Drug Administration today, August 31, 2012 approved Xtandi® (MDV3100) (enzalutamide) capsules to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Approved for prostate cancer patients previously treated with chemotherapy, Xtandi was reviewed under the FDA’s priority review [...]

By Malecare|2017-10-19T10:50:57-04:00August 31st, 2012|Advanced Prostate Cancer, Chemo Therapy Failure, enzalutamide, FDA, Uncategorized, Understanding APC, Xtandi|0 Comments

A FDA Approval for Zytiga Before Chemotherapy – On the Horizon

On Wednesday, Johnson & Johnson said that the FDA will conduct a fast review of Zytiga as a treatment for men with advanced prostate cancer who have not received chemotherapy. The Food and Drug Administration has agreed to conduct a six-month review of Zytiga which should be completed in mid-December, 2012. According to representatives from [...]

By Malecare|2012-08-31T16:05:51-04:00August 31st, 2012|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments

Early Access Program Needs Your Help – Share Your Experiences to Insure A Continuing Program

Dr. Moyad has been the driving force behind getting the Early Access Program for drugs to treat advanced prostate cancer. Along with the Early Access Committee he has arranged for an early access (before the formal approval from the FDA) for both Zytiga and now MDV3100. (you can read about the programs including how to [...]

By Malecare|2017-10-19T10:50:57-04:00August 27th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Early/Expanded Access Programs, Uncategorized|0 Comments

Malecare

About Malecare